Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EARS

Auris Medical (EARS) Stock Price, News & Analysis

Auris Medical logo

About Auris Medical Stock (NASDAQ:EARS)

Advanced Chart

Key Stats

Today's Range
$0.30
$0.43
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume
830,271 shs
Average Volume
3.10 million shs
Market Capitalization
$3.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

EARS Stock Analysis - Frequently Asked Questions

Auris Medical Holding Ltd. (NASDAQ:EARS) issued its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $1.60.

Auris Medical shares reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXDW), Novavax (NVAX), OPKO Health (OPK), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/11/2017
Today
6/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EARS
Fax
N/A
Employees
132,200
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.57 per share
Price / Book
0.19

Miscellaneous

Free Float
N/A
Market Cap
$3.43 million
Optionable
Not Optionable
Beta
1.17
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:EARS) was last updated on 6/2/2025 by MarketBeat.com Staff
From Our Partners